Segmental Reporting

6 Months Ended

Jun. 30, 2014

Segment Reporting [Abstract]

Segment Reporting Disclosure

21.       Segmental reporting

Shire comprises a single operating and reportable segment engaged in the research, development, licensing, manufacturing, marketing, distribution and sale of innovative specialist medicines to meet significant unmet patient needs.

This segment is supported by several key functions: a Pipeline group, consisting of R&D and Business Development, which prioritizes its activities towards late stage development programs across a variety of therapeutic areas, while focusing its pre-clinical development activities primarily in Rare Diseases; a Technical Operations group responsible for the Company's global supply chain; and an In-line marketed products group focuses on commercialized products. The In-Line marketed products group currently consists of four commercial units focused exclusively on commercial delivery to drive optimum performance of currently marketed products. The business is also supported by a simplified, centralized corporate function group. None of these functional groups meets all of the criteria to be an operating segment.

This single operating and reportable segment is consistent with the financial information regularly reviewed by the Executive Committee (which is Shire's chief operating decision maker) for the purposes of evaluating performance, allocating resources, and planning and forecasting future periods.

In the periods set out below, revenues by major product were as follows:

6 months to,	June 30,	June 30,
	2014	2013
	$’M	$’M
	___________	___________
VYVANSE	710.7	598.7
ELAPRASE	280.7	263.5
LIALDA/MEZAVANT	272.5	238.0
REPLAGAL	244.8	228.1
CINRYZE	215.5	-
INTUNIV	182.3	168.1
ADDERALL XR	184.9	212.1
VPRIV	176.6	164.1
FIRAZYR	163.9	91.2
PENTASA	135.5	144.6
FOSRENOL	88.1	84.4
XAGRID	55.0	49.9
Other product sales	67.2	63.4
	____________	____________
Total product sales	2,777.7	2,306.1
	____________	____________